(Q44476390)

3 December 2017

title

Deferasirox-induced renal impairment in children: an increasing concern for pediatricians (English)

1 reference

3 December 2017

Laurence Dubourg

1

1 reference

3 December 2017

Céline Laurain

2

1 reference

3 December 2017

Bruno Ranchin

3

1 reference

3 December 2017

Corinne Pondarré

4

1 reference

3 December 2017

Aoumeur Hadj-Aïssa

5

1 reference

3 December 2017

Dominique Sigaudo-Roussel

6

1 reference

3 December 2017

Pierre Cochat

7

1 reference

3 December 2017

publication date

24 April 2012

1 reference

3 December 2017

1 reference

3 December 2017

volume

27

1 reference

3 December 2017

issue

11

1 reference

3 December 2017

page(s)

2115-2122

1 reference

Iron loading and its clinical implications

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Concepts and goals in the management of transfusional iron overload.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Deferasirox for transfusion-related iron overload: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Long-term efficacy and safety of deferasirox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Acute interstitial nephritis due to deferasirox: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Fanconi syndrome due to deferasirox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Acute renal failure and Fanconi syndrome due to deferasirox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Acquired Proximal Renal Tubular Dysfunction in β-Thalassemia Patients Treated With Deferasirox

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Adaptation of an enzymatic polyfructosan assay to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

New equations to estimate GFR in children with CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Renal function in children with beta-thalassemia major and thalassemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Renal dysfunction in patients with thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Development of tridentate iron chelators: from desferrithiocin to ICL670.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Cystatin C levels in patients with beta-thalassemia during deferasirox treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Desferrithiocin analogues and nephrotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

Renal Fanconi Syndrome Secondary to Deferasirox: Where There Is Smoke There Is Fire

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2170-4

[Arterial blood pressure in 17,067 children and adolescents. Variation with age and height (author's transl)]

21 January 2018

1 reference

12 December 2020

A formula to estimate the approximate surface area if height and weight be known. 1916.

1 reference

12 December 2020

Renal function in pediatric patients with beta-thalassemia major

1 reference

12 December 2020

Acute changes in renal function associated with deferoxamine therapy

1 reference

12 December 2020

Deferasirox treatment may be associated with reversible renal Fanconi syndrome

1 reference

12 December 2020

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major

1 reference

12 December 2020

Reversible Fanconi syndrome in a pediatric patient on deferasirox

1 reference

12 December 2020

Renal tubular function in beta-thalassemia

1 reference

12 December 2020

[Dangerous drugs for the kidney]

1 reference

12 December 2020

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload

1 reference

12 December 2020

10.1007/S00467-012-2170-4

Identifiers

DOI

1 reference

3 December 2017

1 reference